Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection
OBJECTIVES: The magnitude of HIV viral rebound following ART cessation has consequences for clinical outcome and onward transmission. We compared plasma viral load (pVL) rebound after stopping ART initiated in primary (PHI) and chronic HIV infection (CHI). DESIGN: Two populations with protocol-indic...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Public Library of Science
2012
|
| _version_ | 1797090191228272640 |
|---|---|
| author | Hamlyn, E Ewings, F Porter, K Cooper, D Tambussi, G Schechter, M Pedersen, C Okulicz, J McClure, M Babiker, A Weber, J Fidler, S Phillips, R |
| author_facet | Hamlyn, E Ewings, F Porter, K Cooper, D Tambussi, G Schechter, M Pedersen, C Okulicz, J McClure, M Babiker, A Weber, J Fidler, S Phillips, R |
| author_sort | Hamlyn, E |
| collection | OXFORD |
| description | OBJECTIVES: The magnitude of HIV viral rebound following ART cessation has consequences for clinical outcome and onward transmission. We compared plasma viral load (pVL) rebound after stopping ART initiated in primary (PHI) and chronic HIV infection (CHI). DESIGN: Two populations with protocol-indicated ART cessation from SPARTAC (PHI, n = 182) and SMART (CHI, n = 1450) trials. METHODS: Time for pVL to reach pre-ART levels after stopping ART was assessed in PHI using survival analysis. Differences in pVL between PHI and CHI populations 4 weeks after stopping ART were examined using linear and logistic regression. Differences in pVL slopes up to 48 weeks were examined using linear mixed models and viral burden was estimated through a time-averaged area-under-pVL curve. CHI participants were categorised by nadir CD4 at ART stop. RESULTS: Of 171 PHI participants, 71 (41.5%) rebounded to pre-ART pVL levels, at a median of 50 (95% CI 48-51) weeks after stopping ART. Four weeks after stopping treatment, although the proportion with pVL ≥ 400 copies/ml was similar (78% PHI versus 79% CHI), levels were 0.45 (95% CI 0.26-0.64) log(10) copies/ml lower for PHI versus CHI, and remained lower up to 48 weeks. Lower CD4 nadir in CHI was associated with higher pVL after ART stop. Rebound for CHI participants with CD4 nadir >500 cells/mm(3) was comparable to that experienced by PHI participants. CONCLUSIONS: Stopping ART initiated in PHI and CHI was associated with viral rebound to levels conferring increased transmission risk, although the level of rebound was significantly lower and sustained in PHI compared to CHI. |
| first_indexed | 2024-03-07T03:14:57Z |
| format | Journal article |
| id | oxford-uuid:b57dab01-79f6-4b3d-a151-7804721ecc04 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:14:57Z |
| publishDate | 2012 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:b57dab01-79f6-4b3d-a151-7804721ecc042022-03-27T04:33:45ZPlasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infectionJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b57dab01-79f6-4b3d-a151-7804721ecc04EnglishSymplectic Elements at OxfordPublic Library of Science2012Hamlyn, EEwings, FPorter, KCooper, DTambussi, GSchechter, MPedersen, COkulicz, JMcClure, MBabiker, AWeber, JFidler, SPhillips, ROBJECTIVES: The magnitude of HIV viral rebound following ART cessation has consequences for clinical outcome and onward transmission. We compared plasma viral load (pVL) rebound after stopping ART initiated in primary (PHI) and chronic HIV infection (CHI). DESIGN: Two populations with protocol-indicated ART cessation from SPARTAC (PHI, n = 182) and SMART (CHI, n = 1450) trials. METHODS: Time for pVL to reach pre-ART levels after stopping ART was assessed in PHI using survival analysis. Differences in pVL between PHI and CHI populations 4 weeks after stopping ART were examined using linear and logistic regression. Differences in pVL slopes up to 48 weeks were examined using linear mixed models and viral burden was estimated through a time-averaged area-under-pVL curve. CHI participants were categorised by nadir CD4 at ART stop. RESULTS: Of 171 PHI participants, 71 (41.5%) rebounded to pre-ART pVL levels, at a median of 50 (95% CI 48-51) weeks after stopping ART. Four weeks after stopping treatment, although the proportion with pVL ≥ 400 copies/ml was similar (78% PHI versus 79% CHI), levels were 0.45 (95% CI 0.26-0.64) log(10) copies/ml lower for PHI versus CHI, and remained lower up to 48 weeks. Lower CD4 nadir in CHI was associated with higher pVL after ART stop. Rebound for CHI participants with CD4 nadir >500 cells/mm(3) was comparable to that experienced by PHI participants. CONCLUSIONS: Stopping ART initiated in PHI and CHI was associated with viral rebound to levels conferring increased transmission risk, although the level of rebound was significantly lower and sustained in PHI compared to CHI. |
| spellingShingle | Hamlyn, E Ewings, F Porter, K Cooper, D Tambussi, G Schechter, M Pedersen, C Okulicz, J McClure, M Babiker, A Weber, J Fidler, S Phillips, R Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection |
| title | Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection |
| title_full | Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection |
| title_fullStr | Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection |
| title_full_unstemmed | Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection |
| title_short | Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection |
| title_sort | plasma hiv viral rebound following protocol indicated cessation of art commenced in primary and chronic hiv infection |
| work_keys_str_mv | AT hamlyne plasmahivviralreboundfollowingprotocolindicatedcessationofartcommencedinprimaryandchronichivinfection AT ewingsf plasmahivviralreboundfollowingprotocolindicatedcessationofartcommencedinprimaryandchronichivinfection AT porterk plasmahivviralreboundfollowingprotocolindicatedcessationofartcommencedinprimaryandchronichivinfection AT cooperd plasmahivviralreboundfollowingprotocolindicatedcessationofartcommencedinprimaryandchronichivinfection AT tambussig plasmahivviralreboundfollowingprotocolindicatedcessationofartcommencedinprimaryandchronichivinfection AT schechterm plasmahivviralreboundfollowingprotocolindicatedcessationofartcommencedinprimaryandchronichivinfection AT pedersenc plasmahivviralreboundfollowingprotocolindicatedcessationofartcommencedinprimaryandchronichivinfection AT okuliczj plasmahivviralreboundfollowingprotocolindicatedcessationofartcommencedinprimaryandchronichivinfection AT mcclurem plasmahivviralreboundfollowingprotocolindicatedcessationofartcommencedinprimaryandchronichivinfection AT babikera plasmahivviralreboundfollowingprotocolindicatedcessationofartcommencedinprimaryandchronichivinfection AT weberj plasmahivviralreboundfollowingprotocolindicatedcessationofartcommencedinprimaryandchronichivinfection AT fidlers plasmahivviralreboundfollowingprotocolindicatedcessationofartcommencedinprimaryandchronichivinfection AT phillipsr plasmahivviralreboundfollowingprotocolindicatedcessationofartcommencedinprimaryandchronichivinfection |